Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02502071 · ClinicalTrials.gov registry record · Phase 4

Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes

A Phase 4 study of Type 1 Diabetes and Diabetic Kidney Disease, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 4
Development phase
45
Enrollment target
1
Study location

NCT02502071 is a Phase 4 study of Type 1 Diabetes and Diabetic Kidney Disease that has completed, run by University of Colorado, Denver. The registered enrollment target is 45 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02502071, a Phase 4 study of Type 1 Diabetes and Diabetic Kidney Disease, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 4
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether alkalinization of urine uric acid by 2 doses of sodium bicarbonate (1950mg) over 24-hours reduces precipitation and crystallization of urine uric acid over in adults with type 1 diabetes.

Interventions

  • DRUG sodium bicarbonate

Study Locations (1)

Colorado

  • Barbara Davis Center for Diabetes - Aurora

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2017-01
Est. Completion 2017-08
Phase Phase 4

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT02502071

The ClinicalTrials.gov registry entry for NCT02502071 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which sodium bicarbonate is the first listed.

NCT02502071 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT02502071 about?

NCT02502071 is a clinical study titled "Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes". The purpose of this study is to determine whether alkalinization of urine uric acid by 2 doses of sodium bicarbonate (1950mg) over 24-hours reduces precipitation and crystallization of urine uric acid over in adults with type 1 diabetes.

What is the current status of trial NCT02502071?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2017-01. Estimated completion is 2017-08.

What conditions does trial NCT02502071 study?

This clinical trial studies the following conditions: Type 1 Diabetes, Diabetic Kidney Disease, Diabetic Nephropathy.

What interventions are being tested in trial NCT02502071?

The interventions under investigation include: sodium bicarbonate (DRUG).

Who is sponsoring clinical trial NCT02502071?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02502071 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.